TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04948463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin and Tazobactam for Injection
Description: Given if patient has no known allergies, until ANC recovery at 100mg/kg (max 4g) 6 hourly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime Injection
Description: Given if patient has non life-threatening hypersensitivity (preferred option), until ANC recovery at 50mg/kg (max 2g) 8 hourly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime Injection
Description: If non life-threatening hypersensitivity (second option), given until ANC recovery at 50mg/kg (max 2g) 8 hourly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin Injection
Description: If life-threatening hypersensitivity given with ciprofloxacin, given until ANC recovery at 15mg/kg (max 500mg) 6 hourly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin Injection
Description: Given until ANC recovery at 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: If life-threatening hypersensitivity given with vancomycin, given until ANC recovery at 10 mg/kg (max 400 mg) 12 hourly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin and Tazobactam for Injection
Description: Given if patient has no known allergies at 100mg/kg (max 4g) 6 hourly, stopping 48 hours post-fever resolution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime Injection
Description: If non life-threatening hypersensitivity (preferred option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime Injection
Description: If non life-threatening hypersensitivity (second option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Injection
Description: If life-threatening hypersensitivity given with ciprofloxacin at 15mg/kg (max 500mg) 6 hourly, stopping 48 hours post-fever resolution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin Injection
Description: At 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s, stopping 48 hours post-fever resolution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: If life-threatening hypersensitivity given with vancomycin at 10 mg/kg (max 400 mg) 12 hourly, stopping 48 hours post-fever resolution
Study: NCT05782582

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Package investigation
Description: Investigations performed on a single visit, according to arm description

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound registration with Cadscore® and added risk calculation
Description: Recording of cardiac diastolic sounds enabling the calculation of a risk score.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard investigation
Description: Sequential investigations according to arm description
Study: NCT06315855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Intervention (THI)
Description: The THI is a 6-month intervention. On a monthly basis, the survivor will be queried via telehealth (zoom or smart phone) oral and health related symptoms by nurse practitioner or navigator. Based on the initial imaging and the monthly assessments, the patients will be provided with tools and instructions for oral health maintenance which may consist of mucositis management and/or diet and lifestyle counseling. All participants will be provided a Resource directory that is to be used to identify a dentist that is best suited for him/her. Post intervention, follow-up assessments will be conducted at 6-, 9- and 12-months post randomization.
Study: NCT05423002

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flickering light stimuli
Description: The intervention will be exposed to flickering lights (≤200 lux). More specifically, the participants will be asked to be exposed to a specified flickering light (1Hz, 30 seconds On, and 30 seconds OFF) for 2 hours starting at their habitual bedtime (HBT).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Constant light stimuli
Description: The intervention will be exposed to constant background lights (≤200 lux). The participants will be asked to be exposed to a specified constant light for 2 hours starting at their habitual bedtime (HBT).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dim light
Description: This light condition is the baseline (≤10 lux).
Study: NCT06087952

Intervention type: OTHER
Group type: OTHER
Intervention: Randomised treatment advice (discontinue vs continue after 3 months)
Description: Randomisation to continue or discontinue anticoagulant therapy in 1:1 ratio stratified on risk category of L-TRRiP and VTE-BLEED score

Intervention type: OTHER
Group type: OTHER
Intervention: Randomised treatment advice (discontinue vs continue after 3 months)
Description: Randomisation to continue or discontinue anticoagulant therapy in 1:1 ratio stratified on risk category of L-TRRiP and VTE-BLEED score

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VTE-BLEED score
Description: Predict bleeding risk during extended anticoagulant treatment (high or low) using the VTE-BLEED score

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VTE-BLEED score
Description: Predict bleeding risk during extended anticoagulant treatment (high or low) using the VTE-BLEED score

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VTE-BLEED score
Description: Predict bleeding risk during extended anticoagulant treatment (high or low) using the VTE-BLEED score

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VTE-BLEED score
Description: Predict bleeding risk during extended anticoagulant treatment (high or low) using the VTE-BLEED score

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: L-TRRiP score
Description: Predict VTE recurrence risk after anticoagulant discontinuation (high, intermediate or low) using the L-TRRiP score

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: L-TRRiP score
Description: Predict VTE recurrence risk after anticoagulant discontinuation (high, intermediate or low) using the L-TRRiP score

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: L-TRRiP score
Description: Predict VTE recurrence risk after anticoagulant discontinuation (high, intermediate or low) using the L-TRRiP score

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: L-TRRiP score
Description: Predict VTE recurrence risk after anticoagulant discontinuation (high, intermediate or low) using the L-TRRiP score

Intervention type: OTHER
Group type: OTHER
Intervention: Advise to continue anticoagulant treatment after 3 months
Description: Advise to continue anticoagulant treatment after 3 months for patients with high VTE recurrence and low bleeding risk

Intervention type: OTHER
Group type: OTHER
Intervention: Advise to discontinue anticoagulant treatment after 3 months
Description: Advise to discontinue anticoagulant treatment after 3 months for patients with low VTE recurrence risk
Study: NCT05713071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Endoscopic Antral Myotomy
Description: BEAM will be performed using a standard gastric peroral endoscopic myotomy (G-POEM) technique, however with the myotomy targeting only the antrum and leaving the pyloric ring intact. G-POEM is commonly and widely employed for gastric emptying and nutritional issues and is covered by most insurance plans. This involves injecting fluid into the submucosal space, making a mucosal incision to enter the submucosal space, and tunneling along the antrum to the pylorus. A myotomy is then performed, however, in BEAM the pyloric ring is spared and the myotomy is only performed in the antrum. The incision is then closed with clips. No endoscopic suturing will be performed.
Study: NCT04796038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon dilatation
Description: Patient will be treated with balloon dilatation either stand-alone (POBA) or followed by stent implantation.
Study: NCT05111288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF)
Description: Pulsed electromagnetic field (PEMF) therapy is a noninvasive technique, which provides low field electromagnetic stimulation. The therapy of PEMF is achieved by altering biological and physiological systems via low energy and non-ionizing electromagnetic fields.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive Pulsed electromagnetic field therapy (PEMF)
Description: PEMF device that turns on but does not provide any electromagnetic stimulation
Study: NCT05366712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker Trident® II HA coated cementless acetabula component
Description: New acetabula component.
Study: NCT04445662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Escalating financial rewards for saliva cotinine levels \<30 ng/mL, assessed 10 times over 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: * Day 1 - 3: 0.5 mg daily~* Day 4 - 7: 0.5 mg twice daily~* Day 8 - Week 12: 1 mg twice daily~* Dose/schedule may be adjusted based on medical history and clinician judgement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: * Day 1 - 3: 0.5 mg daily~* Day 4 - 7: 0.5 mg twice daily~* Day 8 - Week 12: 1 mg twice daily~* Dose/schedule may be adjusted based on medical history and clinician judgement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco coaching
Description: 5 one-on-one tobacco cessation coaching sessions over 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco coaching
Description: 5 one-on-one tobacco cessation coaching sessions over 12 weeks
Study: NCT05935176

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCV4
Description: 2 dose of MCV4 on Day 0 and Month 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCV4
Description: 2 dose of MCV4 on Day 0 and Month 3
Study: NCT06530277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REMINDer (A digital environmental enrichment intervention)
Description: REMINDer adapts the REMIND program (Nicotra et al., 2022) for telehealth, integrating cognitive, motor, sensory, emotional, and social stimulation through music, dance-based movement, and mindfulness. The program consists of 2 online sessions/week for 60 minutes each over 6 weeks, led by trained facilitators experienced in dance movement therapy and mindfulness exercises. Sessions are divided into welcome/warm-up (10 min), training (40 min), and relaxation/feedback (10 min) phases. Using a structured manual, participants perform exercises that address the program's multimodal stimulation. The REMINDer program is delivered in a group setting via an online videoconferencing system. The intervention, no intervention (AB) group undergoes the training program between t1 and t2 and then resumes their normal lifestyle from t2 to t3. The no intervention, intervention group (BA) maintains its normal lifestyle from t1 to t2 and then participates in the training program from t2 to t3.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REMINDer (A digital environmental enrichment intervention)
Description: REMINDer adapts the REMIND program (Nicotra et al., 2022) for telehealth, integrating cognitive, motor, sensory, emotional, and social stimulation through music, dance-based movement, and mindfulness. The program consists of 2 online sessions/week for 60 minutes each over 6 weeks, led by trained facilitators experienced in dance movement therapy and mindfulness exercises. Sessions are divided into welcome/warm-up (10 min), training (40 min), and relaxation/feedback (10 min) phases. Using a structured manual, participants perform exercises that address the program's multimodal stimulation. The REMINDer program is delivered in a group setting via an online videoconferencing system. The intervention, no intervention (AB) group undergoes the training program between t1 and t2 and then resumes their normal lifestyle from t2 to t3. The no intervention, intervention group (BA) maintains its normal lifestyle from t1 to t2 and then participates in the training program from t2 to t3.
Study: NCT06482086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 8/10/12 mg qd, po. Stop the medication for one week after taking it for two weeks.
Study: NCT04850521

Intervention type: OTHER
Intervention: Remote monitoring
Description: patient-facing app + connected spirometer + connected pulse oximeter + clinician view portal
Study: NCT05909150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride solution 3,5%
Description: Patients will receive 150 mL HSS 3,5% intravenous twice daily for 3 days after heart transplantation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride solution 0,9%
Description: Patients will receive 150 mL NS 0,9% intravenous twice daily for 3 days after heart transplantation.
Study: NCT04846296

Intervention type: OTHER
Intervention: Questionnaire
Description: The QLPSD, developed in Spain, was the first questionnaire designed to evaluate HRQoL in adolescents with spinal deformities. It has shown good validity and reliability. English, French and Persian versions of the QLPSD have been developed and validated. Good reliability and ease of use are mentioned in these versions. The QLPSD was designed to examine adolescents with spinal deformities and measure the effect of orthotic and surgical treatments on QoL.
Study: NCT06482086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8/12 mg qd, po.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 0.4 g bid, po.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: 0.3 g bid, po.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg qd, po.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500 mg qd, po.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib + Trametinib
Description: Dabrafenib 150 mg bid, po+Trametinib 2 mg qd, po.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib 60mg qd, po.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Vandetanib 300mg qd, po.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Entrectinib 600mg qd，po.
Study: NCT06556407

Intervention type: DEVICE
Group type: OTHER
Intervention: renal denervation
Description: ultrasound based renal denervation
Study: NCT06482086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralsetinib
Description: 400mg qd, po.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Description: 100mg qd，po
Study: NCT04881682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunoadsorption
Description: see arm/group description

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunoglobulins
Description: see arm/group description
Study: NCT06567002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6552
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6552
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6552
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6552
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6552
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6552
Description: Oral Administration
Study: NCT04106115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg IV infusion every 4 weeks for up to 7 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S-488210/S-488211
Description: S-488210/S-488211 is given as a 1 mL subcutaneous (SC) injection of S-488210/Montanide emulsion and a 1 mL SC injection of S-488211/Montanide emulsion starting the day after first dose of durvalumab and continuing weekly for 6 doses and then every 2 weeks for a further 9 doses
Study: NCT05325203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ongericimab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ongericimab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT06282861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trelegy Ellipta 100/62.5/25Mcg Inh 30D
Description: Product to be used according to specifications. 1 inhalation daily for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimica
Description: As per product specifications
Study: NCT06475586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: 0.25mg 4 weeks, 0.5mg per 4 weeks and 1.0mg per 4 weeks, totally 12 weeks
Study: NCT05871775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized exercise
Description: After selective functional movement evaluation, customized interventions for each patient

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stabilization exercise
Description: Neck stabilization exercise and sensorimotor program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General exercise
Description: General mobility exercise and strength exercise program
Study: NCT05036759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: intravenously injected with 68Ga-FAPI
Study: NCT05923983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decision support
Description: In the intervention group, the pharmaceutical validation will be based on routine care, often on entry to a ward and by analysis of all the alerts produced by the CDSS. Some alerts will result in a pharmaceutical intervention being provided to the medical team

Intervention type: OTHER
Group type: OTHER
Intervention: Will not receive Clinical Decision Support
Description: In the control group, the pharmaceutical validation will be based on routine care, often on entry to a ward or in a particular situation
Study: NCT05043129

Intervention type: BIOLOGICAL
Intervention: Biological/Vaccine: SARS-COV-2 VACCINE
Description: The antibody titer and adverse reactions were observed.

Intervention type: BIOLOGICAL
Intervention: Biological/Vaccine: SARS-COV-2 VACCINE
Description: The antibody titer and adverse reactions were observed.
Study: NCT06504706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Matcha Tea
Description: Japanese tea rich in antioxidants and Catechins

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Green Tea
Description: Green tea rich in catechins
Study: NCT06024460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-pharmacological treatment strategy
Description: Acupuncture, elctroacupuncture, spinal manual therapy, motion style acupucnture treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological treatment strategy
Description: Prescription medication, injection therapy, nerve blocks, or other pharmacological interventions commonly used for managing lumbar disc herniation.~This group is treated using the above treatment strategies, and no drug is specified.
Study: NCT06312046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HiBalance-MS
Description: See arm description for intervention group.
Study: NCT06461312

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined pulsed radiofrequency of the pudendal nerve with ganglion impar block
Description: Combined pulsed radiofrequency of the pudendal nerve with ganglion impar block
Study: NCT04296006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustained Release d-amphetamine
Description: Twice daily administration of active or placebo d-amphetamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sustained Release d-amphetamine
Description: Twice daily administration of active or placebo d-amphetamine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Money
Description: Three money values offered as alternatives to cocaine

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Money
Description: Three money values offered as alternatives to cocaine
Study: NCT06282861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duaklir
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultibro
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulunar
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xoterna
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anoro
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Laventair
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiolto Respimat
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yanimo
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foradil
Description: As per product specifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Broncoral
Description: As per product specifications
Study: NCT05497895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5% thymoquinone (TQ) gel
Description: Mode of Administration In Group I patients, the lipid based TQ gel (5%) will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performing the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior and after its application. The patients will be instructed to not eat for 30 minutes following its application.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SRP and placebo
Description: In Group II patients, the placebo gel will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performs the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior to and after its application. The patients will be instructed to not eat for 30 minutes following its application